Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00352 |
| Species: | Homo sapiens |
| Position : | chr13:28840000-28850000 |
| Year: | 2023 |
| Title: | Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | B-cell acute lymphoblastic leukemia |
| PMID: | 38016946 |
| MONDO: | MONDO:0004945 |
| Tissue: | Bone Marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | SEM |
| CVCL ID: | CVCL_0095 |
| Cell Type: | B lymphoblast |
| Cell Ontology ID: | CL:0000945 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq, RNA-seq, Hi-C, ATAC-seq, Capture-C |
| Low Throughput Method: | CRISPR Knockout, CRISPRi, qRT-PCR, Western blot, Competitive Proliferation Assay, Flow Cytometry, In Vivo Transplantation Assay |
| Target gene : | GFI1 |
| TF name : | HOXA9 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| HOXA9 | TGF_beta_Receptor | netpath | 220 |